Asia Deal Watch: SV Investment And Orange Grove Will Team Up On New Company Effort
Executive Summary
Takeda spins out Oak Hill Bio, Lupin and Axantia will co-develop filgrastim biosimilar and Xbiome licenses skin ulcer candidate from Aurealis.
You may also be interested in...
Dr Reddy’s Brings In Range Of Mature Novartis Brands In India
With an ‘India First’ strategy previously communicated, Dr Reddy’s Laboratories has brought in several Novartis India Established Medicines. “We intend to evaluate capabilities to maintain business continuity,” the company says.
It’s Deal Time: Aurobindo on M&A, Divestment Path
What value do PE funds see in Aurobindo Pharma’s injectables business as the company looks for a partner? Why is Aurobindo looking for acquisitions in India as it sets a domestic revenue target of $133m in three years from the formulations business? Scrip takes a look.
China's First Biotech M&A Deal In 2022 Signals Busy Season Ahead?
CSPC acquires a little-known Guangzhou biotech to kick-start China's pharma sector consolidation in 2022, a key goal outlined in the country's recent 14th Five-Year Plan.